

the gp100 sequence to said mammal in an effective amount to stimulate the production of immune cells.

C1
cont

31. (amended) An immunogenic composition for immunizing a mammal comprising an immunogenically-effective amount of gp100 (SEQ ID NO:27) or an immunogenic peptide [having] consisting essentially of 5-20 contiguous amino acids within the gp100 sequence in a pharmacologically acceptable carrier.

REMARKS

Applicants respectfully request reconsideration in view of the claim amendments and the following remarks.

Claims 29-31 are pending in the instant application. Applicants respectfully request reconsideration in view of the claim amendments and the following remarks.

Claims 29-31 have been rejected under 35 U.S.C. §112, second paragraph for using the term “having”. The Examiner asserts that this term is ambiguous as it is unclear whether this recitation is to be interpreted as open language or as closed language.

Applicants respectfully disagree with this rejection. However, in order to facilitate allowance of the pending claims, applicants have amended to claims to address the Examiner’s concerns. Reconsideration and withdrawal of this 112 rejection is respectfully requested.

Claims 29-31 have been rejected under 35 U.S.C. §102(b) as being anticipated by WO 92/21767. Applicants respectfully disagree with this rejection. However, applicants assert the rejection is rendered moot by the instant claims. Applicants respectfully request reconsideration and withdrawal of the §102(b) rejection. Applicants respectfully request